Prevention and termination of pregnancy in rats by cabergoline, a dopamine agonist

in Reproduction
Authors:
H. Negishi
Search for other papers by H. Negishi in
Current site
Google Scholar
PubMed
Close
and
S. S. Koide
Search for other papers by S. S. Koide in
Current site
Google Scholar
PubMed
Close
Free access

Sign up for journal news

The objective of the study was to clarify the potency and action of cabergoline, a dopamine agonist, in preventing and terminating pregnancy in rats. Cabergoline administered s.c. to female rats on days 1, 2 and 3 of pregnancy prevented implantation of the fertilized ova and development of the embryos. The drug was 100% effective at doses of 10 μg kg−1 day−1 or higher. Serum progesterone determined on day 8 of pregnancy was significantly reduced in rats treated with cabergoline at doses of 5 μg kg−1 day−1 and higher, whereas serum concentrations of oestradiol remained unchanged. Cabergoline at doses of 10 and 20 μg kg−1 day−1 administered s.c. on days 7, 8 and 9 of pregnancy was partially effective (43 and 50%, respectively) in terminating pregnancy, whereas at doses of 30 μg kg−1 day−1 and higher, pregnancy was terminated in all treated rats. Serum concentrations of progesterone on days 12 and 16 of pregnancy were significantly lower in rats treated with doses of 10 μg kg−1 day−1 or higher. Serum prolactin determined on day 4 of pregnancy in rats treated with cabergoline at the effective dose of 10 μg kg−1 day−1 on days 1, 2 and 3 of pregnancy was significantly reduced to 1.7 ± 0.62 ng ml−1 from a pretreatment value of 16.0 ng ml−1. The lowest effective dose of cabergoline in reducing serum prolactin determined on day 8 of pregnancy was 20 μg kg−1 day−1. The present results support the hypothesis that cabergoline acts by inhibiting prolactin production or release, thereby inhibiting progesterone biosynthesis by the ovary.

 

  • Collapse
  • Expand